Cardiac masses are uncommon entities that can be broadly classified as non-neoplastic or neoplastic. Some normal anatomical structures (such as a prominent crista terminalis) and some non-neoplastic lesions (such as intracavitary thrombi) can mimic a true cardiac neoplasm.

Neoplastic masses are subdivided into metastatic, primary benign and primary malignant tumors. Because most cardiac masses are not amenable to biopsy, non-invasive imaging plays a pivotal role in their evaluation; imaging is also important if surgical resection is contemplated because accurate delineation of a lesion’s margins helps predict the likelihood of complete removal (1).

A multi-modality imaging approach is usually required when investigating a suspected cardiac mass, with the choice of imaging technique guided by patient-related factors, local availability, and provider expertise. The primary goals of imaging are the following:

1) to ascertain if a mass is present;
2) to define a mass’s location, extent, and relationships; and
3) to distinguish between potentially benign and malignant lesions.

Transthoracic echocardiography (TTE) is usually the initial imaging technique and is robust for identifying an intracardiac mass, provided that the acoustic windows are adequate. In patients with a large body habitus or emphysema, the evaluation is frequently limited. Transesophageal echocardiography (TEE) affords improved spatial resolution, which is especially useful for small masses (<1 cm) and valvular lesions. However, it is invasive and, as with TTE, provides only limited tissue characterization, often making it impossible to confidently distinguish between thrombi and benign and malignant tumors (1).

In recent years, magnetic resonance imaging (MRI) has become the technique of choice for further differentiation and characterization of a cardiac mass because it has numerous advantages over echocardiography, including an unrestricted field of view and superior soft-tissue resolution (2). However, MRI is heavily reliant on patient cooperation to obtain high quality images and is not suitable for all patients. It is specifically contraindicated in those patients with claustrophobia or an implanted ferromagnetic device.

Recent technologic advances in multi-detector computed tomography (MDCT), including improvements in spatial and temporal resolution in conjunction with ECG-gating, have made MDCT an extremely useful modality for evaluating a cardiac mass (3). ECG-gated MDCT should also be considered Superior to MRI in some respects as it has superior spatial resolution (0.4–0.6 mm vs. 1–2 mm), can definitively characterize fat and calcification using attenuation measurements and can simultaneously evaluate the coronary arteries.
ECG-gating, however, there are often significant motion artifacts, which can preclude detecting small lesions and cause blurring of the margins of larger lesions, thus limiting the assessment of local extension. ECG-gating minimizes cardiac motion-related artifacts, thus enabling more precise evaluation of lesion margins. Retrospective ECG-gating (continuous data acquisition through the cardiac cycle) is preferred over prospective ECG-gating (data acquisition at a single time point) because it allows cine loops to be reconstructed, and lesion mobility can be assessed. Retrospective ECG-gating carries a much higher radiation burden than prospective ECG-gating (10–15 mSv vs. 2–5 mSv), however. Scanning from the carina to the cardiac apex usually provides a sufficient volume of coverage. We typically use 70 mL of iohexol contrast medium at 5 mL/s followed by a 50%:50% contrast:saline flush, which helps maintain some opacification in the right heart chambers but which is not so dense as to create streak artifacts. A follow-up study 2–3 min later without additional contrast injection can help with tissue characterization because delayed enhancement within a mass signifies contrast accumulation in an expanded interstitium, such as within areas of tumor necrosis. Delayed phase images may also be a useful problem-solving technique in cases where evaluations with echocardiography and/or MRI have been incomplete or inconclusive (Fig. 1). Prospective ECG-gating with a low tube voltage (80 kV) and normal tube current (600–800 mAs) has been recommended to minimize radiation exposure while maximizing the contrast-to-noise ratio between the tumor tissue and normal myocardium in delayed phase MDCT (5).

Indeed, several consensus statements now include ECG-gated MDCT as a recommended technique for evaluating cardiac masses (4). Occasionally, a cardiac mass may be detected for the first time on non-ECG-gated thoracic MDCT studies performed for an unrelated indication, and radiologists should be familiar with its various characteristic features so that they can generate a meaningful differential diagnosis. This article describes the MDCT appearances of the most common cardiac pseudotumors and neoplasms.

Multidetector CT technique
To provide isotropic spatial resolution, MDCT studies are ideally performed using at least a 64-detector row system (3). Non-ECG gated MDCT with intravenous contrast infusion may be adequate for localizing a cardiac mass. In the absence of ECG-gating, however, there are often significant motion artifacts, which can preclude detecting small lesions and cause blurring of the margins of larger lesions, thus limiting the assessment of local extension. ECG-gating minimizes cardiac motion-related artifacts, thus enabling more precise evaluation of lesion margins. Retrospective ECG-gating (continuous data acquisition through the cardiac cycle) is preferred over prospective ECG-gating (data acquisition at a single time point) because it allows cine loops to be reconstructed, and lesion mobility can be assessed. Retrospective ECG-gating carries a much higher radiation burden than prospective ECG-gating (10–15 mSv vs. 2–5 mSv), however. Scanning from the carina to the cardiac apex usually provides a sufficient volume of coverage. We typically use 70 mL of iohexol contrast medium at 5 mL/s followed by a 50%:50% contrast:saline flush, which helps maintain some opacification in the right heart chambers but which is not so dense as to create streak artifacts. A follow-up study 2–3 min later without additional contrast injection can help with tissue characterization because delayed enhancement within a mass signifies contrast accumulation in an expanded interstitium, such as within areas of tumor necrosis. Delayed phase images may also be a useful problem-solving technique in cases where evaluations with echocardiography and/or MRI have been incomplete or inconclusive (Fig. 1). Prospective ECG-gating with a low tube voltage (80 kV) and normal tube current (600–800 mAs) has been recommended to minimize radiation exposure while maximizing the contrast-to-noise ratio between the tumor tissue and normal myocardium in delayed phase MDCT (5).
Pseudotumors
A variety of non-neoplastic masses can mimic cardiac tumors and should be recognized as such to avoid misdiagnosis.

Intracavitary thrombi
Thrombi are the most common intracardiac masses and are the major differential for any intracavitary lesion. Most thrombi develop in regions of slow flow or around a nidus, such as a central venous catheter tip. Common locations for a thrombus are the left ventricle, in association with aneurysm formation after myocardial infarctions, and the left atrial appendage, in patients with atrial fibrillation (Fig. 2). On MDCT, a thrombus appears as a well-circumscribed, low-attenuation mass that usually does not enhance, even on delayed phase scans. Rarely, chronic thrombi may show some peripheral enhancement due to the presence of a fibrous pseudocapsule (Fig. 3). Chronic thrombi may occasionally contain calcifications. The main differential is atrial myxoma, for which there can be considerable overlap of MDCT imaging results. Indeed, a recent study by Scheffel et al. (6) showed that prolapse through the atrioventricular valve orifice is the only reliable feature favoring myxoma over left atrial thrombus on ECG-gated MDCT; lesion size, origin, and attenuation characteristics were poor discriminators.

Lipomatous hypertrophy
Lipomatous hypertrophy of the atrial septum describes an excess of normal brown fat in this region and is considered an anatomical variant rather than a true neoplasm. Unlike an interatrial lipoma, which is the main differential diagnosis, it characteristically spares the fossa ovalis, which gives it a dumbbell-like appearance (Fig. 4) (7).
Pericardial cyst

Pericardial cysts are benign congenital lesions that arise from the pericardium but do not communicate with the pericardial space. They have an incidence of 1:100,000 and are most commonly located at the right anterior cardiophrenic angle, although they may occur anywhere in the mediastinum. They are simple unilocular lesions that contain water-based fluid without internal septa. Although usually asymptomatic, some patients may complain of symptoms that include chest pain and persistent cough. MDCT shows a homogenous, non-enhancing mass of water attenuation.

Bronchogenic cyst

Bronchogenic cysts are well-circumscribed, thin-walled, fluid-filled structures that are thought to arise from the bronchial tree as a result of abnormal budding of the ventral foregut. Approximately two-thirds are situated within the mediastinum, most often in a subcarinal or right paratracheal location. MDCT shows a sharply marginated mediastinal mass consisting of soft-tissue or water attenuation.

Pericardial hematoma

Pericardial hematomas usually result from prior cardiac surgery, trauma or myocardial infarction. In an acute context, compression of the cardiac chambers may impede diastolic ventricular filling and lead to hemodynamic compromise. Chronic hematomas tend to become organized, often calcify, and are a frequent cause of constrictive pericarditis. Calcification is manifest as a signal void on all MRI pulse sequences, and MDCT is the modality of choice for a definitive characterization.

Metastases

Metastases to the heart and pericardium are 100–1000 times more common than primary cardiac tumors. They generally appear late in the course of the primary disease, and isolated cardiac involvement is rare in the absence of multi-organ dissemination. The spreading mechanisms include direct extension and hematogenous and venous seeding, with hematogenous seeding being the most common route for tumors of bronchial and breast origin. The pericardium is the most frequent site of involvement, which often takes the form of a malignant effusion. Aside from pericardial effusions, metastases may also manifest on MDCT as multiple soft-tissue density masses.
Primary cardiac tumors

Primary cardiac tumors are rare, with an estimated lifetime incidence of 0.02% (10). The approximate frequencies of the subtypes, taken from the surgical and pathology literature, are presented in Table. The clinical manifestations are non-specific and depend on size, tumor type, and location. While some remain clinically silent, others present with symptoms, such as intracardiac obstruction, tamponade, arrhythmias, and systemic embolization (11).

Benign primary tumors

Most benign primary cardiac tumors can be completely resected with minimal morbidity and mortality, and many patients enjoy survival similar to that of the general population (10). The typical features include a well-defined mass that involves a single cardiac chamber and has a narrow transition zone.

Myxoma

Myxomas account for 50% of all benign primary cardiac tumors and may arise from pluripotent residual mesenchymal cells in the subendocardium (11). The vast majority arise within the atria, with 75% occurring on the left and 15%–20% on the right side. A narrow attachment point at the fossa ovalis of the atrial septum is typical, but they can originate from any endocardial surface, including the valves (1).
Resection is required for definitive diagnosis and to prevent major complications, especially strokes secondary to the systemic embolization of left-sided tumor fragments (1).

Most myxomas appear on MDCT as pedunculated low-attenuation intracavitary masses (Fig. 9), although some myxomas are broad based and contain calcifications. Large lesions may prolapse through the mitral or tricuspid valve orifices (Fig. 10) (6). Arterial phase enhancement is usually not apparent, but delayed enhancement is recognized and typically heterogeneous (6). Thrombus is the major differential diagnosis, as has been previously discussed.

**Fibroelastoma**

Fibroelastomas are endocardial papillomas composed of collagen and elastic-tissue fibers, with an endothelial covering and a connective tissue pedicle. They can arise from any endocardial surface, but the majority are found on the aortic and mitral valves (12). Most are small (<1 cm) and remain clinically silent, but there is the potential for embolization into the systemic or pulmonary circulation from accumulated thrombi.

Because of their small size, TEE is the optimal means of detection, and MDCT assessment is rarely indicated; however, they are occasional findings on MDCT appearing as a focal low attenuation valve nodule (3). Fibroelastomas are typically located away from the valvular free edge, and the valve function is usually preserved; this outcome is in contrast to endocarditis-induced vegetation, which also appears as a low attenuation lesion but which typically involves the valvular free edge and causes valve destruction and dysfunction (1). In our experience, we have found multi-sequence MRI more useful than MDCT in the preoperative work-up of suspected fibroelastomas (Fig. 11).

**Lipoma**

Lipomas are slow growing neoplasms composed of mature adipose tissue. They may arise from the epicardial, myocardial or endocardial surfaces, including the atrial septum (7). Most patients are asymptomatic, but these tumors are a recognized cause of arrhythmias, especially atrial fibrillation. Large lipomas can sometimes produce

<table>
<thead>
<tr>
<th>Table. The approximate frequency of benign and malignant primary cardiac tumors, adapted from references 10 and 11</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Percentage</strong></td>
</tr>
<tr>
<td><strong>Benign</strong></td>
</tr>
<tr>
<td>Myxoma</td>
</tr>
<tr>
<td>Fibroelastoma</td>
</tr>
<tr>
<td>Lipoma</td>
</tr>
<tr>
<td>Fibroma</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Total</td>
</tr>
<tr>
<td><strong>Malignant</strong></td>
</tr>
<tr>
<td>Angiosarcoma</td>
</tr>
<tr>
<td>Sarcomas with myofibroblastic differentiation</td>
</tr>
<tr>
<td>Undifferentiated pleomorphic sarcoma</td>
</tr>
<tr>
<td>Osteosarcoma</td>
</tr>
<tr>
<td>Leiomyosarcoma</td>
</tr>
<tr>
<td>Fibrosarcoma</td>
</tr>
<tr>
<td>Liposarcoma</td>
</tr>
<tr>
<td>Myofibroblastic tumor</td>
</tr>
<tr>
<td>Rhabdomyosarcoma</td>
</tr>
<tr>
<td>Primary lymphoma</td>
</tr>
<tr>
<td>Pericardial tumor</td>
</tr>
<tr>
<td>Mesothelioma</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

Figure 9. A small left atrial myxoma, which was an incidental finding. This axial MDCT image shows a well-circumscribed, low-attenuation mass in relation to the atrial septum (arrows). A thrombus can have an identical CT appearance; however, this lesion failed to resolve with anticoagulation and was subsequently surgically resected, which confirmed the diagnosis of myxoma. RA, right atrium; LV, left ventricle.
Figure 11. a–d. A fibroelastoma of the tricuspid valve, which was an incidental finding in a contrast-enhanced thoracic MDCT study performed for a different indication. An MRI was performed for further characterization, and the findings were typical for a papillary fibroelastoma. An axial non-ECG-gated MDCT image (a) showing a tiny, well-circumscribed low-attenuation nodule within the right ventricular cavity (arrows). A four-chamber SSFP MRI image (b) and a coronal SSFP MRI image (c) showing that the nodule is attached to the tricuspid sub-valvular apparatus (arrows). A delayed gadolinium-enhanced image (d) acquired 10 min following the injection of 0.1 mmol/kg gadolinium-DTPA and using an inversion-recovery pulse sequence to attenuate the signal from the normal myocardium. It shows complete absence of enhancement within the nodule (arrow), which supports of a benign etiology. The morphological information provided by the MRI is most consistent with papillary fibroelastoma. LV, left ventricle.

Figure 10. a–c. A large left atrial myxoma in a patient who presented with palpitations and embolic phenomena. A diastolic phase echocardiogram image (a) showing a large mass prolapsing through the mitral valve orifice (arrows). An axial ECG-gated MDCT image (b) showing that the lesion is attached to the atrial septum by a narrow pedicle (arrow) and has low attenuation and a villous margin. A two-chamber MDCT image (c) in diastole showing lesion prolapse through the mitral valve orifice (arrow), which is considered a reliable means of distinguishing myxomas from thrombi. RA, right atrium; RV, right ventricle; LV, left ventricle.
symptoms secondary to their compressive effects. Lipomas are difficult to diagnose using echocardiography due to an extremely variable echo-pattern (1). Both MRI and MDCT are reliable techniques for definitively characterizing fat. On MDCT, a lipoma appears as a well-circumscribed lesion of homogeneous fat attenuation (-50 to -150 HU) (Fig. 12).

**Fibroma**

Fibromas are well-circumscribed aggregates of collagen and fibroblasts that arise in an intra-myocardial location, most often in the ventricular septum or left-ventricular free wall. Although histologically benign, they can cause ventricular arrhythmias and sudden death from interference with conduction pathways (2, 11). The majority occur in infants and children, but presentation in adulthood also occurs. On MDCT, a fibroma appears as a discrete focal soft-tissue attenuation mass (Fig. 13) that sometimes contains foci of calcification (3).

**Other benign tumors**

Rhabdomyomas usually occur in association with tuberous sclerosis. They are common in childhood but tend to regress spontaneously and are rarely encountered in adults. On MDCT, they manifest as single or multiple solid homogeneous masses arising in the left ventricular myocardium (1).

Hemangiomas are vascular malformations composed of blood-filled, endothelial-lined, and thin-walled spaces. Most patients are asymptomatic, and they are often discovered incidentally at cardiac surgery, although exertional dyspnea is a recognized presentation. On MDCT, hemangiomas appear as well-defined expansile masses within the ventricular myocardium/pericardium and may contain calcifications; enhancement is usually avid and prolonged (3).

Paragangliomas originate from cardiac neuroendocrine cells, and patients typically present with symptoms of excess catecholamines, e.g., hypertension and flushing. Resection is usually curative provided it is complete. On MDCT, paragangliomas appear as discrete, heterogeneous low-attenuation masses in the typical cardiac ganglia distribution pathways, i.e., at the root of the great vessels and along the walls of the atria (2).
Malignant primary tumors

Imaging findings suggestive of a malignant cardiac tumor include a right atrial location, involvement of more than one cardiac chamber, size >5 cm, hemorrhagic pericardial effusion, a broad base of attachment, extension into the mediastinum or great vessels, and delayed enhancement (13).

Sarcomas

Sarcomas account for the majority of primary malignant cardiac tumors and are the second most common primary tumor after myxomas. Histologically, they are classified into three main subgroups: angiosarcomas, sarcomas with myofibroblastic differentiation, and rhabdomyosarcomas (11).

Angiosarcomas

Angiosarcomas are highly aggressive neoplasms composed of irregular vascular channels lined by anaplastic epithelial cells. The peak incidence is in the fourth decade, and there is a strong male predominance. The majority originate in the right atrium; they typically fill this chamber, with infiltration along the pericardium and into the tricuspid valve and right coronary artery (1, 2). The clinical presentation usually occurs at an advanced stage, with symptoms of right heart failure and/or cardiac tamponade (11). Distant metastases are present in up to 90% of the cases at the time of diagnosis; these metastases most frequently occur in the lungs, liver, and brain. The prognosis is dire, with few patients surviving beyond 12 months (14). MRI is the technique of choice for assessing the precise relationship of the tumor to adjacent structures if resection or debulking surgery is being contemplated (Fig. 14). On imaging studies, angiosarcomas typically appear as large masses with a heterogeneous composition, often in association with sheet-like pericardial thickening and a hemorrhagic pericardial effusion.

Sarcomas with myofibroblastic differentiation

This group of tumors is diverse and may contain heterologous elements, such as bone. They occur predominately in adulthood and are sub-classified as undifferentiated sarcomas, leiomyosarcomas, fibrosarcomas, liposarcomas, and osteosarcomas. They most often originate along the posterior wall of the left atrium and tend to exhibit slow infiltrative growth patterns (3). Their infiltrative nature is readily appreciated on MDCT, which helps differentiate them from thrombi and myxoma (Fig. 15). Calculations should alert physicians to the possibility of an osteosarcoma. Liposarcomas rarely contain sufficient amounts of macroscopic fat to permit confident diagnosis based on their morphologic imaging characteristics (2).

Primary cardiac lymphomas

Primary cardiac lymphoma describes a disease that is confined to the heart or pericardium, which distinguishes it from the more common case of cardiac involvement by non-Hodgkin’s lymphoma (3). Most of these lymphomas occur in immunocompromised patients, are of B-cell origin, and follow an aggressive clinical course. Unlike other primary cardiac malignancies, they often have a favorable response to chemotherapy. The right atrium is reported to be the most common site, but unlike sarcomas, they are less likely to have necrosis and rarely involve the valves (1). The imaging findings are non-specific,
Figure 15. **a–c.** A sarcoma with myofibroblastic differentiation in a patient with symptoms of left heart failure that was evaluated with ECG-gated MDCT. A two-chamber arterial phase MDCT image **(a)** showing a lobulated mass arising from the roof of left atrium (arrows) and abutting the anterior mitral valve leaflet (arrowhead). A coronal arterial phase image **(b)** through the body of left atrium showing that the mass is attached to its lateral wall and is infiltrating into the left inferior pulmonary vein (arrows) and breaching the pericardium. An axial delayed-phase image **(c)** showing patchy areas of late enhancement (arrows), which implies differential washout kinetics within this malignant lesion. LV, left ventricle; LA, left atrium.

Figure 16. **a, b.** A rhabdomyosarcoma in a patient with chest pain and weight loss. An axial MDCT image **(a)** at the level of the aortic root showing tumor infiltration surrounding the left anterior descending coronary artery (arrows). Also note the presence of a pulmonary metastasis (arrowhead). Axial MDCT image **(b)** at the level of the left atrium shows a large infiltrative mass centered on the left ventricular free wall (arrows). Ao, aortic root.
but they usually appear as isoattenuating relative to myocardium on MDCT. Several morphologic subtypes have been described, including a solitary nodular mass and a diffuse infiltrative process, often in association with extensive pericardial effusion.

**Primary pericardial malignancy**

Mesothelioma can arise from the pericardial mesothelial cell layer. An association with asbestos exposure is assumed but yet to be established, owing to the rarity of these tumors. They cause progressive pericardial encasement with breathlessness and chest pain; the prognosis is dire, with few surviving beyond 12 months from the time of diagnosis (15).

MDCT is superior to MRI for these tumors because the lung parenchyma and pleura can be simultaneously evaluated for signs of asbestos-related disease, i.e., calcified pleural plaques, diffuse pleural thickening, and interstitial fibrosis. Pericardial mesotheliomas appear as multiple enhancing and coalescing pericardial masses that envelop the pericardial space but rarely infiltrate deep into the underlying myocardium. As with pleural mesotheliomas, a long delay time (70–90 s) is recommended for the initial set of images because this tumor is typically poorly vascularized and may not be optimally visualized in an arterial phase study (Fig. 17).

Pericardial synovial sarcomas are extremely aggressive tumors that are composed of spindle and epithelioid cells, with imaging features that show considerable overlap with angiosarcomas. A heterogeneously enhanced multi-lobulated mass with extensive pericardial infiltration and deep invasion on MDCT has been described.

As a conclusion, MDCT can provide useful complimentary information to echocardiography and MRI for assessing a suspected cardiac mass; in some instances, it is the modality of choice for a definitive characterization. In particular, MDCT offers high spatial resolution, fast acquisition times and the ability to definitively characterize fat and calcification. Radiologists should be familiar with the key distinguishing features of both neoplastic and non-neoplastic masses, as highlighted in this review.

**Conflict of interest disclosure**

The authors declared no conflicts of interest.

**References**